Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
Patent 4464378 Issued on August 7, 1984. Estimated Expiration Date: 
August 7, 2001. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 7, 2001. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesSalicylate anti-inflammatory composition Patent #: 4275059 InventorAssigneeApplicationNo. 06/258308 filed on 04/28/1981US Classes:514/282, One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)514/284, Tetracyclo ring system having the six-membered hetero ring as one of the cyclos514/289, Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)514/429, Carbocyclic ring bonded directly to the five-membered hetero ring546/44, One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)546/45, Nitrogen or divalent chalcogen double bonded directly to carbocyclic ring of the pentacyclo ring system (e.g., morphinones, etc.)546/46, A single chalcogen is bonded directly to ring carbon of the pentacyclo ring system (e.g., desoxy morphine, etc.)546/61Tetracyclo ring system having the six-membered hetero ring as one of the cyclosExaminersPrimary: Friedman, Stanley J.Attorney, Agent or FirmInternational ClassesA61K 9/00 (20060101)A61K 31/35 (20060101) A61K 31/485 (20060101) AbstractThe invention provides a novel method of administering narcotic antagonists, narcotic analgesics and related compounds, and novel dosage forms containing those compounds which are adapted for nasal administration. The nasal dosage forms disclosed include solutions, suspensions, gels and ointments. Especially preferred compounds which can be advantageously administered in accordance with the invention include naloxone, naltrexone, nalbuphine, levorphanol, buprenorphine, butorphanol, Ɗ9 -tetrahydrocannabinol (THC), cannabidiol (CBD) and levonantradol. |
| ||||||||||||||
